Shots:

• NMPA has granted BTD to socazolimab for cervical cancer. Socazolimab is licensed from Sorrento to COF for the greater China territory
• Lee intends to file an NDA to the NMPA and request a fast-track conditional approval of socazolimab to treat cervical cancer in Q2’21. Additionally- the companies are planning to expand their partnership for the license of additional therapeutic antibodies from Sorrento’s G-MAB library to treat hematologic and solid tumors
• Socazolimab is a fully human anti-PD-L1 mAb and has demonstrated outstanding efficacy and safety profile in the clinical trials in cervical cancer patients

 ­ Ref: Sorrento | Image: News Medical